User login
With the development of ever-more-sophisticated endovascular intervention systems, limb ischemia need no longer be an automatic sentence of lifelong pain or amputation.
But the burgeoning supply of these specialized devices brings its own challenge to the area of endovascular intervention. Which device is best for which patient? And which have strong data to back up their claims of effectiveness? Thursday’s session, “New Devices for Embolectomy, Clot Removal, and Embolization,” will offer some guidance.
“The presentations represent significant further advances in methods and technology that can treat patients with severe, limb-threatening, and life-altering vascular diseases,” said Dr. McNamara. “Also, comparisons are made between competing new technologies. This will be very helpful in deciding which method and/or technology to use. And it will, I think, be very helpful in deciding whether to use interventional or open surgical treatments.“These presentations will not only guide the vascular specialist, but help to substantiate that the interventional techniques continue to be more and more effective. This information could, and should, be shared with primary care physicians.”
This point can’t be underestimated, Dr. McNamara noted. Primary care physicians are on the front line of venous disorders, and should know that there are good treatment options for many patients – treatments than can save limbs and vastly improve pain and function.
“An increasing percentage of patients should be referred for consultation and possible treatments for arterial and venous disease. This will result in decreased morbidity and improved quality of life for an increasing number of patients.”
Surgeons should expect to see more and more such patients as the U.S. population continues to age – and effective treatment not only benefits each individual, but society as a whole.
“The disease significantly decreases the quality of life, and reduces the independence of our aging population. This significantly increases the costs, and increases the burden to society and families of the growing percentage of our population in their ‘Golden Years.’”
The session opens with a lecture by Dr. Ali Amin, a vascular surgeon from West Reading, Pa. He will discuss the role of mechanical thrombectomy and thrombolysis in acute limb ischemia, and when open surgery rather than endovascular intervention is indicated
Dr. Jos C. van den Berg of the University of Bern, Switzerland, will then tackle how to utilize suction techniques and devices to deal with the embolic complications of peripheral vascular interventions.
Rotarex and Aspirex, two mechanical debulking devices created by Straub Med, will be the topic of a presentation by Dr. Michael K.W. Lichtenberg chief of the Angiology Clinic and Venous Center at Klinikum Arnsberg, Germany.
There will be three presentations on thrombectomy with the Indigo System by Penumbra. Indigo provides mechanical clot engagement and vacuum extraction and can be used in both arteries and veins.
Dr. James F. Benenati, of Florida International University Herbert Wertheim College of Medicine, and Dr. Richard R. Saxon of San Diego Imaging, will discuss the PRISM Registry data. The registry recently reported that mechanical aspiration with the Indigo device is a safe and effective option for the treatment of peripheral or visceral arterial occlusions either as a frontline therapy or in patients who failed thrombolysis.
Dr. Frank R. Arko of Carolinas Healthcare System, will share his thoughts on why the Indigo system is an excellent choice for clot removal, and how it decreases the need for lytic therapy.
Dr. George L. Adams, MD, Director of Cardiovascular and Peripheral Vascular Research will make the case for why the Indigo system could be a “game-changer” in the treatment of acute limb ischemia and visceral artery thomboses and emboli.
Dr. Andrej Schmidt of the University Clinic of Leipzig, Germany, will discuss the advantages and limitations of several other Penumbra products, including the Ruby Coil for peripheral embolization, and the Penumbra Occlusion Device (POD). He will also touch on the Lantern microcatheter, Penumbra’s newest product, launched in April. The low-profile, high-flow microcatheter can pass through the distal vasculature, but can also be used for high-flow contrast injections.
Finally, Dr. Aaron Fischman of Mount Sinai Medical Center, will speak on the challenge of endovascular rescue procedures for acute visceral ischemia from thromboembolism.
Session 62
“New Devices for Embolectomy, Clot Removal, and Embolization”
4:32 p.m. – 5:30 p.m.
Grand Ballroom West, 3rd Floor
With the development of ever-more-sophisticated endovascular intervention systems, limb ischemia need no longer be an automatic sentence of lifelong pain or amputation.
But the burgeoning supply of these specialized devices brings its own challenge to the area of endovascular intervention. Which device is best for which patient? And which have strong data to back up their claims of effectiveness? Thursday’s session, “New Devices for Embolectomy, Clot Removal, and Embolization,” will offer some guidance.
“The presentations represent significant further advances in methods and technology that can treat patients with severe, limb-threatening, and life-altering vascular diseases,” said Dr. McNamara. “Also, comparisons are made between competing new technologies. This will be very helpful in deciding which method and/or technology to use. And it will, I think, be very helpful in deciding whether to use interventional or open surgical treatments.“These presentations will not only guide the vascular specialist, but help to substantiate that the interventional techniques continue to be more and more effective. This information could, and should, be shared with primary care physicians.”
This point can’t be underestimated, Dr. McNamara noted. Primary care physicians are on the front line of venous disorders, and should know that there are good treatment options for many patients – treatments than can save limbs and vastly improve pain and function.
“An increasing percentage of patients should be referred for consultation and possible treatments for arterial and venous disease. This will result in decreased morbidity and improved quality of life for an increasing number of patients.”
Surgeons should expect to see more and more such patients as the U.S. population continues to age – and effective treatment not only benefits each individual, but society as a whole.
“The disease significantly decreases the quality of life, and reduces the independence of our aging population. This significantly increases the costs, and increases the burden to society and families of the growing percentage of our population in their ‘Golden Years.’”
The session opens with a lecture by Dr. Ali Amin, a vascular surgeon from West Reading, Pa. He will discuss the role of mechanical thrombectomy and thrombolysis in acute limb ischemia, and when open surgery rather than endovascular intervention is indicated
Dr. Jos C. van den Berg of the University of Bern, Switzerland, will then tackle how to utilize suction techniques and devices to deal with the embolic complications of peripheral vascular interventions.
Rotarex and Aspirex, two mechanical debulking devices created by Straub Med, will be the topic of a presentation by Dr. Michael K.W. Lichtenberg chief of the Angiology Clinic and Venous Center at Klinikum Arnsberg, Germany.
There will be three presentations on thrombectomy with the Indigo System by Penumbra. Indigo provides mechanical clot engagement and vacuum extraction and can be used in both arteries and veins.
Dr. James F. Benenati, of Florida International University Herbert Wertheim College of Medicine, and Dr. Richard R. Saxon of San Diego Imaging, will discuss the PRISM Registry data. The registry recently reported that mechanical aspiration with the Indigo device is a safe and effective option for the treatment of peripheral or visceral arterial occlusions either as a frontline therapy or in patients who failed thrombolysis.
Dr. Frank R. Arko of Carolinas Healthcare System, will share his thoughts on why the Indigo system is an excellent choice for clot removal, and how it decreases the need for lytic therapy.
Dr. George L. Adams, MD, Director of Cardiovascular and Peripheral Vascular Research will make the case for why the Indigo system could be a “game-changer” in the treatment of acute limb ischemia and visceral artery thomboses and emboli.
Dr. Andrej Schmidt of the University Clinic of Leipzig, Germany, will discuss the advantages and limitations of several other Penumbra products, including the Ruby Coil for peripheral embolization, and the Penumbra Occlusion Device (POD). He will also touch on the Lantern microcatheter, Penumbra’s newest product, launched in April. The low-profile, high-flow microcatheter can pass through the distal vasculature, but can also be used for high-flow contrast injections.
Finally, Dr. Aaron Fischman of Mount Sinai Medical Center, will speak on the challenge of endovascular rescue procedures for acute visceral ischemia from thromboembolism.
Session 62
“New Devices for Embolectomy, Clot Removal, and Embolization”
4:32 p.m. – 5:30 p.m.
Grand Ballroom West, 3rd Floor
With the development of ever-more-sophisticated endovascular intervention systems, limb ischemia need no longer be an automatic sentence of lifelong pain or amputation.
But the burgeoning supply of these specialized devices brings its own challenge to the area of endovascular intervention. Which device is best for which patient? And which have strong data to back up their claims of effectiveness? Thursday’s session, “New Devices for Embolectomy, Clot Removal, and Embolization,” will offer some guidance.
“The presentations represent significant further advances in methods and technology that can treat patients with severe, limb-threatening, and life-altering vascular diseases,” said Dr. McNamara. “Also, comparisons are made between competing new technologies. This will be very helpful in deciding which method and/or technology to use. And it will, I think, be very helpful in deciding whether to use interventional or open surgical treatments.“These presentations will not only guide the vascular specialist, but help to substantiate that the interventional techniques continue to be more and more effective. This information could, and should, be shared with primary care physicians.”
This point can’t be underestimated, Dr. McNamara noted. Primary care physicians are on the front line of venous disorders, and should know that there are good treatment options for many patients – treatments than can save limbs and vastly improve pain and function.
“An increasing percentage of patients should be referred for consultation and possible treatments for arterial and venous disease. This will result in decreased morbidity and improved quality of life for an increasing number of patients.”
Surgeons should expect to see more and more such patients as the U.S. population continues to age – and effective treatment not only benefits each individual, but society as a whole.
“The disease significantly decreases the quality of life, and reduces the independence of our aging population. This significantly increases the costs, and increases the burden to society and families of the growing percentage of our population in their ‘Golden Years.’”
The session opens with a lecture by Dr. Ali Amin, a vascular surgeon from West Reading, Pa. He will discuss the role of mechanical thrombectomy and thrombolysis in acute limb ischemia, and when open surgery rather than endovascular intervention is indicated
Dr. Jos C. van den Berg of the University of Bern, Switzerland, will then tackle how to utilize suction techniques and devices to deal with the embolic complications of peripheral vascular interventions.
Rotarex and Aspirex, two mechanical debulking devices created by Straub Med, will be the topic of a presentation by Dr. Michael K.W. Lichtenberg chief of the Angiology Clinic and Venous Center at Klinikum Arnsberg, Germany.
There will be three presentations on thrombectomy with the Indigo System by Penumbra. Indigo provides mechanical clot engagement and vacuum extraction and can be used in both arteries and veins.
Dr. James F. Benenati, of Florida International University Herbert Wertheim College of Medicine, and Dr. Richard R. Saxon of San Diego Imaging, will discuss the PRISM Registry data. The registry recently reported that mechanical aspiration with the Indigo device is a safe and effective option for the treatment of peripheral or visceral arterial occlusions either as a frontline therapy or in patients who failed thrombolysis.
Dr. Frank R. Arko of Carolinas Healthcare System, will share his thoughts on why the Indigo system is an excellent choice for clot removal, and how it decreases the need for lytic therapy.
Dr. George L. Adams, MD, Director of Cardiovascular and Peripheral Vascular Research will make the case for why the Indigo system could be a “game-changer” in the treatment of acute limb ischemia and visceral artery thomboses and emboli.
Dr. Andrej Schmidt of the University Clinic of Leipzig, Germany, will discuss the advantages and limitations of several other Penumbra products, including the Ruby Coil for peripheral embolization, and the Penumbra Occlusion Device (POD). He will also touch on the Lantern microcatheter, Penumbra’s newest product, launched in April. The low-profile, high-flow microcatheter can pass through the distal vasculature, but can also be used for high-flow contrast injections.
Finally, Dr. Aaron Fischman of Mount Sinai Medical Center, will speak on the challenge of endovascular rescue procedures for acute visceral ischemia from thromboembolism.
Session 62
“New Devices for Embolectomy, Clot Removal, and Embolization”
4:32 p.m. – 5:30 p.m.
Grand Ballroom West, 3rd Floor